Description

Remo-M 1000 Tablet

Remo-M 1000 Tablet is a combination oral antidiabetic medication formulated for the management of type 2 diabetes mellitus. Each film-coated tablet contains Remogliflozin Etabonate 100 mg and Metformin Hydrochloride IP 1000 mg.

This combination provides dual action for effective glycemic control in patients whose blood sugar is not adequately managed with diet, exercise, or monotherapy. The film coating ensures easy swallowing, stability, and proper absorption.

. Composition

Excipients are used for stability, controlled disintegration, and coating, without affecting the active ingredients.

. Mechanism of Action

A. Remogliflozin Etabonate (SGLT2 Inhibitor)

• Inhibits sodium-glucose co-transporter 2 in renal proximal tubules.

• Reduces glucose reabsorption in kidneys.

• Promotes urinary glucose excretion.

• Lowers both fasting and postprandial blood glucose.

B. Metformin Hydrochloride (Biguanide)

• Suppresses hepatic glucose production.

• Improves peripheral glucose uptake and insulin sensitivity.

• Does not stimulate insulin secretion, lowering risk of hypoglycemia.

The combination provides complementary mechanisms: increased urinary glucose excretion plus improved insulin sensitivity, for better glycemic control.

. Pharmacokinetics

• Absorption: Both drugs are orally absorbed; Metformin is absorbed primarily in the small intestine.

• Distribution: Metformin minimally protein-bound; Remogliflozin moderately protein-bound.

• Metabolism: Remogliflozin metabolized in liver; Metformin excreted unchanged in urine.

• Excretion: Renal excretion for both drugs and their metabolites.

• Half-life: Supports once or twice daily dosing, depending on physician’s instructions.

. Indications / Therapeutic Uses

• Type 2 diabetes mellitus with inadequate control from diet and exercise.

• Can be used as initial combination therapy or add-on to monotherapy.

• Helps reduce fasting glucose, postprandial glucose, and HbA1c.

. Dosage and Administration

• Typical dose: One tablet once or twice daily, preferably with meals to minimize gastrointestinal side effects from Metformin.

• Swallow whole; do not chew or crush.

• Adjustments may be needed based on renal function, age, or glycemic response.

. Benefits of Combination Therapy

• Dual mechanism addresses both renal glucose excretion and insulin sensitivity.

• Convenient single tablet combination.

• Effective glycemic control with reduced need for multiple tablets.

• May reduce side effects compared to higher doses of monotherapy.

. Side Effects

• Gastrointestinal: nausea, diarrhea, abdominal discomfort (mainly from Metformin).

• Genitourinary: urinary tract or genital infections (Remogliflozin).

• Rare: lactic acidosis (Metformin, particularly in renal impairment).

• Most adverse effects are mild and temporary.

. Precautions

• Use caution in patients with renal or hepatic impairment.

• Monitor blood glucose and renal function regularly.

• Ensure adequate hydration to prevent dehydration and urinary tract infections.

• Not suitable for type 1 diabetes or diabetic ketoacidosis.

• Only use during pregnancy/lactation if prescribed.

. Storage Conditions

• Store in a cool, dry place below 30°C.

• Protect from light and moisture.

• Keep out of reach of children.

. Alternate Brand Options (Remogliflozin + Metformin 1000 mg Combination)

Prices are approximate; actual retail may vary by pharmacy and location.

Remo-M 1000 Tablet is a dual-action oral antidiabetic combination that combines Remogliflozin and Metformin for managing type 2 diabetes mellitus. Its complementary mechanisms — renal glucose excretion plus insulin sensitization — make it effective in controlling fasting and postprandial glucose levels. The tablet is convenient, well-tolerated, and suitable for long-term use under medical supervision. Multiple brands are available in the market for choice and cost flexibility.